SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pkwknk who wrote (70)12/6/1997 4:50:00 PM
From: Sigmund  Read Replies (1) of 178
 
The only thing I can think of is tax loss selling. We will see who is smart and who is not by the end of February. Thr immediate downside is probably $8 to $10 if the approval is not granted with an upside of probably $25 to $30 within a month of approval. Of course these are just gut feels....how would I know. I think the odds of approval are better than 50/50 so that is why I am staying in.

If they need to go before an advisory panel and if that date is established, there should be a positive tone from then on. Hopefully the stock won't slump much the next two weeks. Of course they could get an answer from the FDA at any time including next week so it is risky to try to avoid this next two weeks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News